Literature DB >> 25232425

Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma.

Zeming Liu1, Xiaoyu Li1, Lan Shi1, Yusufu Maimaiti1, Tianwen Chen1, Zhi Li1, Shuntao Wang1, Yiquan Xiong1, Hui Guo1, Wenshan He1, Chunping Liu1, Xiu Nie2, Wen Zeng3, Tao Huang1.   

Abstract

OBJECTIVE: To assess usefulness of cytokeratin 19 (CK19), thyroperoxidase (TPO), Hector Battifora mesothelial epitope-1 (HBME-1) and galectin-3 (GAL3) in evaluation of aggressive behavior of PTCs.
METHODS: All available clinical and pathological data were reviewed in 168 papillary thyroid cancer patients; while the values as predictive markers of PTC were tested by univariate and multivariate analysis.
RESULTS: According to the univariate set of tests, positive expression of CK19 and negative expression of TPO correlated significantly with total tumor diameter (P < 0.05); But there was no association of positive CK19 expression and negative expression of TPO with gender, age, capsular invasion or lymph node metastasis. Moreover, there was no association of positive HBME-1 and galectin-3 expression with clinical aggressive behavior of PTCs.
CONCLUSION: High expression of CK19 and negative expression of TPO indicate total tumor diameter of PTC, but expression of CK19, TPO, HBME-1 and GAL3 has no values in the identification of PTCs with other potentially aggressive behavior.

Entities:  

Keywords:  CK19; HBME-1; TPO; aggressive behavior; galectin-3; papillary thyroid carcinoma

Year:  2014        PMID: 25232425      PMCID: PMC4161585     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  24 in total

1.  [Operation for differentiated thyroid cancer: a experience of 546 cases].

Authors:  Zhi Li; Chun-ping Liu; Lan Shi; Tao Huang
Journal:  Zhonghua Wai Ke Za Zhi       Date:  2008-03-01

2.  The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin.

Authors:  A Durnez; C Verslype; F Nevens; J Fevery; R Aerts; J Pirenne; E Lesaffre; L Libbrecht; V Desmet; T Roskams
Journal:  Histopathology       Date:  2006-08       Impact factor: 5.087

3.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

4.  Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.

Authors:  P S de Matos; A P Ferreira; F de Oliveira Facuri; L V M Assumpção; K Metze; L S Ward
Journal:  Histopathology       Date:  2005-10       Impact factor: 5.087

5.  Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma.

Authors:  Qunzi Zhao; Jie Ming; Chunping Liu; Lan Shi; Xia Xu; Xiu Nie; Tao Huang
Journal:  Ann Surg Oncol       Date:  2012-09-13       Impact factor: 5.344

6.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

7.  Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19.

Authors:  Figen Barut; Nilufer Onak Kandemir; Sibel Bektas; Burak Bahadir; Sevinc Keser; Sukru Oguz Ozdamar
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

8.  Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors.

Authors:  Ivan Paunovic; Tijana Isic; Marija Havelka; Svetislav Tatic; Dubravka Cvejic; Svetlana Savin
Journal:  APMIS       Date:  2011-11-19       Impact factor: 3.205

Review 9.  Management of thyroid cancer.

Authors:  Louiza Vini; Clive Harmer
Journal:  Lancet Oncol       Date:  2002-07       Impact factor: 41.316

10.  Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1.

Authors:  Mary B Casey; Christine M Lohse; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

View more
  14 in total

1.  Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer.

Authors:  Jie Ming; Zeming Liu; Wen Zeng; Yusufu Maimaiti; Yawen Guo; Xiu Nie; Chen Chen; Xiangwang Zhao; Lan Shi; Chunping Liu; Tao Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

2.  Using foci number to predict central lymph node metastases of papillary thyroid microcarcinomas with multifocality.

Authors:  Yawen Guo; Zeming Liu; Pan Yu; Chunping Liu; Jie Ming; Ning Zhang; Maimaiti Yusufu; Chen Chen; Tao Huang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

3.  Associations Between Nucleus Size, and Immunohistochemical Galectin-3, Cytokeratine-19 and Hbme-1 Markers in Thyroid Papillary Carcinoma: A Morphometric Analyze.

Authors:  Hatice Toy; Ozlem Etli; Zeliha Esin Celik; Arsenal Sezgin Alikanoglu
Journal:  Pathol Oncol Res       Date:  2017-11-17       Impact factor: 3.201

4.  CK19 IS A USEFUL MARKER IN DISTINGUISHING FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA FROM BENIGN THYROID LESIONS WITH FOLLICULAR GROWTH PATTERN.

Authors:  F Noroozinia; A Gheibi; B Ilkhanizadeh; A Abbasi
Journal:  Acta Endocrinol (Buchar)       Date:  2016 Oct-Dec       Impact factor: 0.877

5.  THE ASSOCIATION BETWEEN LYMPH NODE METASTASIS AND MOLECULAR MARKERS IN DIFFERENTIATED THYROID CANCER.

Authors:  B I Aydoğan; C C Ersöz; S D Sak; S Güllü
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Jan-Mar       Impact factor: 0.877

6.  Risk Factors for Distant Metastasis in Patients with Minimally Invasive Follicular Thyroid Carcinoma.

Authors:  Yu-Mi Lee; Dong Eun Song; Tae Yong Kim; Tae-Yon Sung; Jong Ho Yoon; Ki-Wook Chung; Suck Joon Hong
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

7.  Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis.

Authors:  Chunping Liu; Tianwen Chen; Zeming Liu
Journal:  World J Surg Oncol       Date:  2016-09-06       Impact factor: 2.754

8.  Galectin-3 may serve as a potential marker for diagnosis and prognosis in papillary thyroid carcinoma: a meta-analysis.

Authors:  Weiwei Tang; Congwei Huang; Chongyin Tang; Jin Xu; Hanjin Wang
Journal:  Onco Targets Ther       Date:  2016-01-22       Impact factor: 4.147

Review 9.  Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).

Authors:  Rui Dong; Min Zhang; Qunying Hu; Shan Zheng; Andrew Soh; Yijie Zheng; Hui Yuan
Journal:  Int J Mol Med       Date:  2017-12-05       Impact factor: 4.101

10.  Galectin-1 is a diagnostic marker involved in thyroid cancer progression.

Authors:  Vanessa Arcolia; Fabrice Journe; Aurore Wattier; Emmanuelle Leteurtre; Florence Renaud; Hans-Joachim Gabius; Myriam Remmelink; Christine Decaestecker; Alexandra Rodriguez; Sébastien Boutry; Sophie Laurent; Sven Saussez
Journal:  Int J Oncol       Date:  2017-07-04       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.